Research Advance of Gene Mutation and Targeted Drug Therapy in Childhood Acute Myeloid Leukemia --Review / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 631-635, 2022.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-928766
Biblioteca responsável:
WPRO
ABSTRACT
The clinical therapeutic regimen for acute myeloid leukemia (AML) is not significantly different between adults and children, which is mostly based on IA (idarubicin and cytosine arabinoside) induction chemotherapy. With the rapid development of sequencing technique, people's understandings towards the molecular and biological abnormalities of AML are increasing, diverse AML gene mutation-based targeted drugs have been rapidly developed and applied. In this review, several commonly gene mutations in AML (such as FLT3, NPM1 and C/EBPA) was described, and the therapeutic effects and differences of targeted drugs that used in clinical treatment or had been reported (like tyrosine kinase inhibitor, IDH1 mutation inhibitor and epigenetic modification inhibitor) in child and adult AML patients were summrized.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Prognóstico
/
Proteínas Nucleares
/
Leucemia Mieloide Aguda
/
Citarabina
/
Tirosina Quinase 3 Semelhante a fms
/
Nucleofosmina
/
Mutação
/
Transtornos Mieloproliferativos
Tipo de estudo:
Estudo prognóstico
Limite:
Adulto
/
Criança
/
Humanos
Idioma:
Chinês
Revista:
Journal of Experimental Hematology
Ano de publicação:
2022
Tipo de documento:
Artigo